What labs should know before selecting a lipoprotein(a) assay | Liquid biopsies considered for assessing cancer treatment resistance | Universal screening for HCV beneficial for at-risk pregnant women
ADVERTISEMENT
November 13, 2018
AACC SmartBrief
SIGN UP ⋅   FORWARD
Top Story
What labs should know before selecting a lipoprotein(a) assay
Laboratories adopting immunoassays for lipoprotein(a), which are designed to identify individuals at increased risk of cardiovascular disease, should determine providers' expectations on the targeted patient population and on guidelines for Lp(a) levels. Labs and clinicians should be aware of racial/ethnic differences in Lp(a) levels, particularly in African-Americans.
Clinical Laboratory News (11/2018) 
LinkedIn Twitter Facebook Email
Start Your Master’s at UChicago in 2019
Biomedical Informatics students at UChicago are tackling healthcare challenges and shaping the industry's future. Start your degree this spring–classes start April 2019. Meet our admissions team and start planning your academic career at UChicago ›
ADVERTISEMENT
Science Briefs
Liquid biopsies considered for assessing cancer treatment resistance
Dr. Joshua Bauml said liquid biopsies have the potential to be an alternative to tissue biopsies in assessing resistance to cancer treatments. "We draw blood and request urine samples from our patients all the time, and the ability to test this serially is very appealing when we consider the fact that resistance develops over time," Bauml said at the 36th Annual Chemotherapy Foundation Symposium.
Specialty Pharmacy Times (11/12) 
LinkedIn Twitter Facebook Email
Universal screening for HCV beneficial for at-risk pregnant women
Universal screening for hepatitis C virus infection is more cost-effective and efficient than risk-based screening in pregnant women, data show.
MedPage Today (free registration) (11/11) 
LinkedIn Twitter Facebook Email
Brown Executive Master in Science & Tech
Brown University's Executive Master in Science and Technology Leadership is a 16-month program combining the business fundamentals of an MBA with personalized leadership for mid-career professionals in science, technology and engineering. Learn more.
ADVERTISEMENT
Policy Briefs
BCBS federal program to cover Interpace Dx's thyroid cancer tests
Interpace Diagnostics has scored a reimbursement win from the Blue Cross Blue Shield federal program for its ThyGeNEXT and ThyraMIR thyroid cancer tests.
Seeking Alpha (11/7) 
LinkedIn Twitter Facebook Email
FDA challenge to curb opioid crisis draws over 200 medtech applications
An innovation challenge launched by the FDA to address the opioid crisis through device-based treatments, mobile apps and diagnostic tests has received more than 200 applications from companies, including Stimwave, Abbott and SPR Therapeutics, hoping to see faster approval for their technologies. The FDA is pleased by "the acknowledgment from developers about the unique and important role medical devices, including digital health technologies like mobile medical apps, have the potential to play in tackling the opioid crisis," FDA Commissioner Scott Gottlieb said.
Reuters (11/9) 
LinkedIn Twitter Facebook Email
AdvaMed to launch major device tax repeal push in lame-duck session
Device industry group AdvaMed is working on a major push to get the medical device tax repeal passed during the lame-duck session, says Greg Crist, head of government affairs and interim chief advocacy officer at AdvaMed. "There may not be a better shot in a long while to get repeal than in these final few weeks," Crist says.
Medtech Insight (free registration) (11/9) 
LinkedIn Twitter Facebook Email
Practice Briefs
HIV test for use with VITROS integrated system wins FDA approval
The FDA has approved Ortho Clinical Diagnostics' VITROS HIV Combo test, or VITROS Immunodiagnostic Products HIV Combo Reagent Pack and Calibrator, to be used with the VITROS 5600 Integrated System.
MD Magazine online (11/6) 
LinkedIn Twitter Facebook Email
FDA grants emergency use authorization for Chembio's Ebola test
FDA grants emergency use authorization for Chembio's Ebola test
(John Wessels/AFP/Getty Images)
Chembio Diagnostic Systems' DPP Ebola Antigen System is the second rapid antigen fingerstick test granted emergency use authorization by the FDA to detect the Ebola virus in patients. It is the first that uses a mobile battery-operated reader, which allows it to provide diagnostic results outside of laboratories.
Medscape (free registration) (11/9),  Seeking Alpha (11/9) 
LinkedIn Twitter Facebook Email
 
Business/Corporate Briefs
Funding round pulls in about $3.7M for Rna Diagnostics
A Series A financing round has pulled in about $3.7 million for Canada-based medical technology firm Rna Diagnostics. Part of the proceeds will be used to commercialize the company's RNA disruption assay.
Northern Ontario Business (Canada) (11/8) 
LinkedIn Twitter Facebook Email
AACC News
Laborastories
Webinar: Healthy Mother/Healthy Baby: Optimal Pregnancy Outcomes through Proper Infectious Disease Testing
November 28, 2018 Join Dr. Judith Monroe as she explains how to ensure your lab is practicing the latest guidelines for testing and diagnosing infectious diseases in pregnant women.
LinkedIn Twitter Facebook Email
Learn more about AACC:
AACC Homepage | AACC Membership | Annual Meeting
Clinical Laboratory News | Clinical Chemistry | JALM
Sign Up
SmartBrief offers 200+ newsletters
Advertise
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Contributing Editor  -  Genna Rollins
Advertising  -  Wynn Hansen
P: 202.470.1149
Editor  -  April Hollis
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2018 SmartBrief, Inc.®
Privacy Policy (updated May 25, 2018) |  Legal Information